Syndax Pharmaceuticals, Inc.
General ticker "SNDX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
Syndax Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 44.6%.
Estimated limits based on current volatility of 1.7%: low 23.69$, high 24.53$
Factors to consider:
- Total employees count: 270 (+46.7%) as of 2024
- Top business risk factors: Operational and conduct risks, Product commercialization failure, Insufficient funding, Intellectual property risks, Manufacturing risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [14.15$, 33.75$]
- 2026-12-31 to 2027-12-31 estimated range: [11.56$, 28.37$]
Financial Metrics affecting the SNDX estimates:
- Negative: with PPE of -6.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -17.73 <= 0.07
- Positive: Investing cash flow per share per price, % of 15.92 > -0.65
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Shareholder equity ratio, % of 12.20 <= 19.49
Short-term SNDX quotes
Long-term SNDX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $23.68MM | $172.35MM |
| Operating Expenses | $229.95MM | $363.35MM | $445.44MM |
| Operating Income | $-229.95MM | $-339.67MM | $-273.08MM |
| Non-Operating Income | $20.59MM | $20.91MM | $-12.34MM |
| Interest Expense | $0.21MM | $4.93MM | $33.78MM |
| R&D Expense | $163.03MM | $241.65MM | $258.78MM |
| Income(Loss) | $-209.36MM | $-318.76MM | $-285.42MM |
| Profit(Loss)* | $-209.36MM | $-318.76MM | $-285.42MM |
| Stockholders Equity | $554.20MM | $288.12MM | $64.63MM |
| Inventory | $0.00MM | $0.37MM | $32.75MM |
| Assets | $612.88MM | $724.82MM | $529.71MM |
| Operating Cash Flow | $-160.60MM | $-274.90MM | $-322.98MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.19MM |
| Investing Cash Flow | $117.61MM | $-219.78MM | $290.04MM |
| Financing Cash Flow | $264.13MM | $353.37MM | $13.68MM |
| Earnings Per Share** | $-2.98 | $-3.72 | $-3.30 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.